发明授权
US08183255B2 N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors
有权
N-嘧啶-4-基-3-氨基 - 吡咯并[3,4-c]吡唑衍生物作为PKC激酶抑制剂
![N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors](/docs/US/2012-05-22/US08183255B2/abs.jpg.600x600.jpg)
- 专利标题： N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors
- 专利标题（中）： N-嘧啶-4-基-3-氨基 - 吡咯并[3,4-c]吡唑衍生物作为PKC激酶抑制剂
-
申请号： US12523965申请日： 2008-02-04
-
公开(公告)号： US08183255B2公开(公告)日： 2012-05-22
- 发明人: Hui Li , Seiji Nukui , Stephanie Anne Scales , Min Teng , Chunfeng Yin
- 申请人： Hui Li , Seiji Nukui , Stephanie Anne Scales , Min Teng , Chunfeng Yin
- 申请人地址： US NY New York
- 专利权人： Pfizer, Inc.
- 当前专利权人： Pfizer, Inc.
- 当前专利权人地址： US NY New York
- 代理机构： Wilson Sonsini Goodrich & Rosati
- 国际申请： PCT/IB2008/000297 WO 20080204
- 国际公布： WO2008/096260 WO 20080814
- 主分类号： A61K31/505
- IPC分类号： A61K31/505
![N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors](/abs-image/US/2012/05/22/US08183255B2/abs.jpg.150x150.jpg)
摘要：
The present invention relates to compounds and pharmaceutically acceptable salts of Formulas A and B: (A) and (B) wherein A, B, R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications, cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disease pression, virus diseases, inflammatory disorders, or diseases in which the liver is a target organ.